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Dr Y. JosephWoo (Philadelphia, Pa). That is a very impressive
amount of work. The microvascular perfusion in the NSAID group
was higher than the other groups, correct?
Dr Robich. Yes, the perfusion in the myocardium, the blood
flow, was increased.
Dr Woo. So how do you explain that in light of all of the other
findings?
Dr Robich. One thing that we didn’t look at was some of the
more upstream arterials that are supplying blood flow. So we are
not sure whether that is playing a part in this as well.
Dr Woo. Did you catheterize the animals?
Dr Robich. They did get catheterized, correct. There were no
differences in Rentrop scores or in myocardial blush grading. So
from an angiographic standpoint, there wasn’t any increase in large,
large vessels.
Dr Woo. So potentially something smaller than what is angio-
graphically visible, but larger than microvascular?
Dr Robich. Exactly, exactly.
Dr John S. Ikonomidis (Charleston, SC). Can you comment on
how you validated the doses that you used in this study?
Dr Robich.Well, basically the way we approached this is those
dosing levels would be standard starting doses in human patients.
The swine weigh about half as much, and so this would represent
a higher dose of drug to the swine. Most of the clinical trials
have demonstrated this increase in adverse events at higher doses
of the drugs, so we wanted to use a higher dose.
Dr Ikonomidis. Have you generated a specific pharmacokinetic
profile for these drugs in swine?
Dr Robich. No, we have not.
Dr Michael E. Jessen (Dallas, Tex). Did you have any animals
die during the course of the experiment?
Dr Robich.We did. We had 1 die in the control group, 3 in the
naproxen group, and 1 in the celecoxib group.
Dr Jessen.Did you necropsy them to find what the causes were?
Dr Robich.Yes, we did a gross necropsy of each animal, Unfor-
tunately, a lot of times animals die in this experiment and other ex-
periments from, we presume, a ventricular arrhythmia, because
there is no real gross or histologic finding to suggest why they
died. Two animals in the naproxen group and 1 in the celecoxib
group showed symptoms that were similar to heart failure. They
were short of breath and breathing tachypneically.
Dr Jessen.How far down the line from the placement of the con-
strictor did this occur?
Dr Robich. All the animals that died in this experiment died
somewhere around the third or fourth week. So they were out
a fair bit. Now, we analyzed that, and obviously in a very small
study like this that didn’t reach statistical significance. But we
did have some deaths.gery c November 2010
